Recent research has provided evidence of the antibody-mediated response to molecular complexes between platelet factor 4 (PF4) and the adenoviral vectors used in COVID-19 vaccines, which appears to be the likely mechanism of the unusual blood clot occurrence associated with adenoviral vector-based COVID-19 vaccines (Baker et al., 2021). This evidence concerns the gene PF4 and COVID-19.